Patents
Patents for C07D 413 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms (64,687)
06/2006
06/22/2006WO2006064757A1 Aminocarboxylic acid derivative and medicinal use thereof
06/22/2006WO2006064375A2 Aminoaryl substituted five-membered ring heterocyclic compounds for the treatment of diseases
06/22/2006WO2006064189A1 Oxadiazole derivatives as dgat inhibitors
06/22/2006WO2006064044A1 Indolinones and their use as antiproliferative agents
06/22/2006WO2006013049A3 Benzyloxy derivatives as maob inhibitors
06/22/2006US20060135770 PARP inhibitors
06/22/2006US20060135769 Farnesyl transferase inhibiting 4-heterocyclyl-quinoline and quinazoline derivatives
06/22/2006US20060135763 delta-opioid receptor agonists as analgesics having reduced side effects and antagonists as immunosuppressants, antiinflammatory agents, neurological, psychiatric , urological and reproductive conditions; e.g. 10-(8-Methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide
06/22/2006US20060135593 N-acyl nitrogen heterocyles as ligands of peroxisome proliferator-activated receptors
06/22/2006US20060135589 1h-Indazole-3-carboxamide compounds as cyclin dependent kinase (cdk) inhibitors
06/22/2006US20060135578 Five-membered heterocyclic compounds
06/22/2006US20060135566 E.g., N-[5-(2-Benzoylamino-4-pyridyl)-4-(3,5-dimethylphenyl)-1,3-thiazol-2-yl]acetamide,; the compounds have adenosine A3 receptor antagonistic activity, a p38 MAP kinase inhibitory action, and a TNF- alpha production-inhibitory action
06/22/2006US20060135554 Novel compounds
06/22/2006US20060135543 N4-(1,4-Benzoxazin-6-yl)-5-fluoro-N2-[3-(N-methylamino)carbonylmethyleneoxyphenyl]-2,4-pyrimidinediamine or a salt, hydrate, solvate and/or N-oxide; inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators; Syk kinase inhibitors
06/22/2006US20060135532 Anticoagulants; antithrombotic agents in the treatment and prevention of thrombosis
06/22/2006US20060135530 Such as (2E)-3-[3-(aminomethyl)-2-isobutyl-4-(4-methylphenyl)quinolin-6-yl]acrylamide; dipeptidyl peptidase IV inhibitors; diabetes, obesity, glucose intolerance
06/22/2006US20060135523 2-substituted 5,6-diaryl-pyrazine derivatives as cb1 modulator
06/22/2006US20060135519 5-aryltetrazole compounds and compositions thereof
06/22/2006US20060135515 Heterocyclic amides and their use treating thromboembolic diseases and tumors
06/22/2006US20060135504 N-(substituted arylmethyl)-4-(disubstituted methyl) piperidines and pyridines
06/22/2006US20060135487 Piperazine derivatives and their use as anti-inflammatory agents
06/22/2006US20060135398 Crystalline modification
06/22/2006US20060134764 Gene cluster involved in safracin biosynthesis and its uses for genetic engineering
06/22/2006DE102004060984A1 New 4-heterocyclyl-benzamide derivatives, useful as antithrombotic agents for treating or preventing e.g. deep vein thrombosis or reocclusion after angioplasty, are inhibitors of factor Xa and other serine proteases
06/22/2006CA2592353A1 Tetrahydroisoquinoline compounds for treatment of cns disorders
06/22/2006CA2591399A1 Aminocarboxylic acid derivative and medicinal use thereof
06/22/2006CA2591033A1 Heterocyclic aspartyl protease inhibitors
06/22/2006CA2590299A1 Piperazinyl-pyridine analogues
06/22/2006CA2589678A1 Novel mch receptor antagonists
06/22/2006CA2589501A1 Indolinones and their use as antiproliferative agents
06/22/2006CA2589363A1 Spiro derivatives as lipoxygenase inhibitors
06/22/2006CA2588909A1 Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor and uses thereof
06/22/2006CA2588384A1 Tetrahydrocarbazoles as active agents for inhibiting vegf production by translational control
06/22/2006CA2588162A1 Oxadiazole derivatives as dgat inhibitors
06/21/2006EP1671950A1 Cinnamoyl derivatives and use thereof
06/21/2006EP1671949A2 Substituted phenylamines and pyridinylamines
06/21/2006EP1670793A1 Antibacterial agents
06/21/2006EP1670792A1 Process for the preparation of chiral propionic acid derivatives
06/21/2006EP1670791A2 Thiophene-based compounds exhibiting atp-utilizing enzyme inhibitory activity, and compositions, and uses thereof
06/21/2006EP1670790A1 Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
06/21/2006EP1670786A1 Quinazoline derivatives
06/21/2006EP1670781A1 Quinoline derivatives and quinazoline derivatives, medicaments containing said compounds, use thereof, and method for the production thereof
06/21/2006EP1670773A1 Methods for the preparation of benzoxazole sulfonamide compounds and intermediates thereof
06/21/2006EP1670770A1 Benzimidazole derivatives, compositions containing them, preparation therof and uses thereof
06/21/2006EP1670768A1 Compounds and methods for treating dyslipidemia
06/21/2006EP1670760A1 Organic compounds
06/21/2006EP1670757A1 Pyrrole and pyrazole derivatives as potentiators of glutamate receptors
06/21/2006EP1670478A2 Heteroaromatic selective inhibitors of neuronal nitric oxide synthase
06/21/2006EP1670476A2 Phenyl pyrrolidine ether tachykinin receptor antagonists
06/21/2006EP1670474A2 Cyclic pyrazinoylguanidine sodium channel blockers
06/21/2006EP1670473A1 Substituted quinolines as protein tyrosine kinase enzyme inhibitors
06/21/2006EP1670460A2 Pyrazole derivatives as cannabinoid receptor modulators
06/21/2006EP1670314A2 Methods and compositions comprising diamines as new anti-tubercular therapeutics
06/21/2006EP1501516B1 A process for the preparation of benazepril hydrochloride
06/21/2006EP1301469B1 Preparation of 4-thioalkylbromobenzene derivatives
06/21/2006EP1286985B1 Substituted pyridine herbicides
06/21/2006EP1208092B1 Sulfonamide derivative as a matrix metalloproteinase inhibitor
06/21/2006CN1791598A Benzimidazole-derivatives as factor Xa inhibitors
06/21/2006CN1791596A Anti-cancer medicaments
06/21/2006CN1791581A Glutamine fructose-y-phosphate amidotransferase (GFAT) inhibitors
06/21/2006CN1791575A Cyanofluoropyrrolidine derivative.
06/21/2006CN1791410A Methods for treating or preventing an inflammatory or metabolic condition by inhibiting JNK
06/21/2006CN1791402A Ophthalmic compositions for treating ocular hypertension
06/21/2006CN1789273A Soluble salt of azithromycin and its preparation process
06/21/2006CN1789250A Optical antimer of a group of nitro imidazole derivatives, preparation method and uses thereof
06/21/2006CN1260227C 5-membered ring heterocyclic compounds with nitrogen
06/21/2006CN1260222C Antagonists of mcp-1 function and methods of use thereof
06/20/2006US7064215 Nitrogen compounds such as 3-(5-morpholin-4-yl-1H-benz-imidazol-2-yl)-1H-indazole and/or isomers, used as immunology modulators, antidiabetic agents, antiogenesis inhibitors or for prophylaxis of Alzheimer's disease
06/20/2006US7064207 Androgen receptor antagonists
06/20/2006US7064202 Camptothecin intermediates and prodrugs and methods of preparation thereof
06/20/2006US7064144 Imidazole derivatives as adenosine deaminase inhibitors
06/20/2006US7064143 4-oxy- or amino-substituted indole-2-carboxy acids, esters and amides, e.g., ethyl 4-hydroxy-1-methyl-1H-indole-2-carboxylate and N-methyl-N-phenethyl 4-hydroxy-1-methyl-1H-indole-2-carboxamide; used for treatment of Alzheimer's disease, anxiety or schizophrenia
06/20/2006US7064135 Antihistamines; anticholesterol agents; cardiovascular disorders; antidiabetic agents; anticancer agents
06/20/2006US7064131 Compounds and methods for inhibiting MRP1
06/20/2006US7064129 e.g., N-(3,5-diamino-6-chloropyrazine-2-carbonyl)-N'-(4-{4-[3-(1H-tetrazol-5-yl)propoxy]phenyl}butyl)guanidine hydrochloride; used to hydrate mucosal surfaces; are absorbed less rapidly, thus have a prolonged pharmacodynamic half-life
06/20/2006US7064124 nuclear factor (NF); inflammatory diseases, autoimmune diseases and viral diseases; 4-(3,4,5,6-tetramethoxy-2-methylbenzyl)-2-benzyloxybenzoic acid or 4-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-yl)methyl-2-benzyloxybenzoic acid, for example
06/20/2006US7064123 substituted acetamides; uses for treating diseases including arthritis, muscular dystrophy, inflammation, tumor invasion, glomerulonephritis, malaria, periodontal disease, and metachromatic leukodystrophy
06/15/2006WO2006062982A2 Urea inhibitors of map kinases
06/15/2006WO2006062478A1 Novel treatment of gastrointestinal disorders
06/15/2006WO2006062224A1 Carboxamide derivative
06/15/2006WO2006061493A1 Substituted indoles, compositions containing them, method for the production thereof and their use
06/15/2006WO2006061379A1 Phenylpiperazine derivatives with a combination of partial dopamine-d2 receptor agonism and serotonin reuptake inhibition
06/15/2006WO2006061377A1 Phenylpiperazine derivatives with a combination of partial dopamine-d2 receptor agonism and serotonin reuptake inhibition
06/15/2006WO2006061376A1 Aryloxyethylamine derivatives with a combination of partial d0pamine-d2 receptor agonism and serotonin reuptake inhibition
06/15/2006WO2006061116A1 Pyrazine dicarboxamides and the use thereof
06/15/2006WO2006034822A8 Novel substituted thiophencarboxylic acid amides, production thereof and use thereof as medicaments
06/15/2006WO2006026135A3 Substituted biaryl piperazinyl-pyridine analogues
06/15/2006WO2006023778A3 Small molecule inhibitors of anti-apoptotic bcl-2 family members and the uses thereof
06/15/2006WO2006002434A3 Novel indazole carboxamides and their use
06/15/2006WO2005056535A8 1,2,3-triazole amide derivatives as inhibitors of cytokine production
06/15/2006US20060128965 chemical intermediates to insecticides and anticoagulant inhibitors of factor Xa having a 1-halophenyl-3-trifluoromethylpyrazole moeity; 1-(1-chloro-2-phenyl)-3-(trifluoromethyl)-1H-pyrazole-5-carboxylic acid
06/15/2006US20060128963 Piperidine derivatives as melanocortin-4 receptor agonists
06/15/2006US20060128961 Process for the production of meso-substituted cyanine dyes
06/15/2006US20060128761 Novel triazole compounds as transforming growth factor (TGF) inhibitors
06/15/2006US20060128759 Substituted isoxazole derivatives and their use in pharmaceutics
06/15/2006US20060128750 Targeting chemokine receptors and interfere with the binding of the natural ligand thereto; antagonists or agonists; protecting target cells from HIV infection; treating HIV or FIV infected patients
06/15/2006US20060128722 Indoles useful in the treatment of androgen-receptor related diseases
06/15/2006US20060128717 Therapeutic agents useful for treating pain
06/15/2006US20060128712 Phenyl-piperazine methanone derivatives, substituted by heterocyclic groups
06/15/2006US20060128706 Apoptosis promoters